2008 Chicago Multidisciplinary Symposium in Thoracic Oncology
Click here to go to the previous page
General Session IX: Experimental Therapeutics B: Early Novel Targets
Program Code:
120
Date:
Friday, November 14, 2008
SPEAKER(S):
Click the plus sign to see more detailed information
about each speaker.
Fadlo Khuri,
M.D., Medical Oncologist,
Emory University School of Medicine
|
(2003–Present)Lecturer, Cancer Pharmacology, Emory University School of Medicine
(2003–Present)Lecturer, Cancer Biology Course, Emory University School of Public Health
(2004 – 2007)Lecturer, Med II – Pathophysiology & Pharmacology, Emory University School of Medicine
(2007 – 2008) Lecturer, Med I – Lung Carcinogenesis, Emory University School of Medicine
-Elected to the American Society of Clinical Investigation in 2007.
-Serves on the editorial board of seven journals which include JCO, Clinical Cancer Research, and has pubished more than 120 peer-reviewed journal articles.
Recent publications:
- (1 article) New England Journal of Medicine 2007
- (1 article) Molecular Cell Biology 2007
- (2 articles) Molecular Pharmacology 2007 & 2008
- (1 article) Cancer Biology Therapy 2007
- (2 articles) Journal of Clinical Oncology 2007 & 2008
- (1 article) Proceedings of the National Academy of Sciences 2008
- (1 article) Clinical Cancer Research 2008
- (1 article) Molecular Cancer Therapy 2008
- (1 article) The American Surgeon 2008
- (1 article) Cancer Research 2008
- (1 article)International Journal of Cancer
|
|
Dr. Rudin is the Associate Director for Clinical Research in the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He co-directs the Upper Aerodigestive Cancer Program, integrating basic and clinical research on cancers of the lung, head and neck, and esophagus. Dr. Rudin directs the Center of Excellence in Translational Research at Johns Hopkins supported by the Flight Attendant Medical Research Institute. He is a member of multiple graduate training programs, and directs a laboratory focused primarily on the development of novel therapeutic strategies for lung cancer. Recent awards include the Burroughs Wellcome Fund Clinical Scientist Award in Translational Research.
|
Ravi Salgia, M.D., University of Chicago
|
I have published on Hsp90 inhibition in EGFR mutant lung cancer (two Cancer Research papers and one review in Journal of Thoracic Oncology).
|
Jerry Shay,
M.D., Vice Chairman,
University of Texas Southwestern
|
Jerry W. Shay is the Vice Chairman of the Department of Cell Biology at The University of Texas Southwestern Medical Center in Dallas, the Associate Director of the Harold Simmon's Comprehensive Cancer Center, and holds the Southland Corporation Distinguished Chair in Aging and Cancer Research. Throughout his career, Dr. Shay has been interested in the relationships between aging and cancer. His seminal work on the relationships of telomerase to aging and cancer has received much international recognition. In 1995 he received the AlliedSignal Award for Research on Aging, the 2001 American Association of Aging Hayflick Award, from 1999-2003 was named an Ellison Medical Foundation Senior Scholar in Aging Research, and in 2004 the Ted Nash Foundation Award. In 2003, Dr. Shay was placed in the Institute for Scientific Investigations as one of the most highly cited scientists in the field of "Molecular Biology and Genetics". In 2006, Science Watch placed Dr. Shay into the Doctors of the Decade (1995-2005) list and he was ranked as the 6th most cited author in the area of General Biomedicine (Science Watch 17:1 2-3, 2006). He has 35 papers that are each cited over 200 times and 60 additional research articles that are cited over 100 times each. In addition to 19 issued patents, Dr. Shay has published over 300 scientific articles, written 50 book chapters and edited 10 books.
Dr. Shay is on the editorial board of several scientific journals and is also a member of biotechnology scientific advisory boards that focus on research in cancer and aging. Finally, Dr. Shay serves as the Chairman of the Scientific Review Committee for the Mary Kay Ash Charitable Foundation.
|
|
Dr. Weichslebuam is Professor and Chairman of the Department of Radiation and Cellular Oncology, and head of the Ludwig Metastsis Center at the University of Chicago Medical Center. He has pubished papers on oligometastsis, (Salama JK, Chmura SJ, Mehta N, Yenice KM, Stadler WM, Vokes EE, Haraf DJ, Hellman S, Weichselbaum RR. An Initial Report of a Radiation Dose Escalation Trial in Patients with One to Five Sites of Metastatic Disease. Clin Ca Research 14: 5255-5259, 2008) He is qualifed to lead this symposium
|
